BioCentury
ARTICLE | Company News

Vertex, Spero Therapeutics deal

June 6, 2016 7:00 AM UTC

Vertex granted Spero worldwide rights to Vertex’s VXc-486/VXc-100 and other undisclosed antibacterial compounds targeting DNA gyrase subunit B (GyrB) and topoisomerase IV Par E subunit (ParE). Verte...